Figure 1From: Potential biomarkers for adult acute myeloid leukemia minimal residual disease assessment searched by serum peptidome profiling Serum peptide fingerprint and cluster analysis of newly diagnosed AML and healthy control. Comparison of serum peptide fingerprints between AML patients and healthy controls showed that peak number and intensity of the two groups were completely different. (Red: AML newly diagnosed group Green: Healthy control group).Back to article page